Evidence map›Paper›PMID 40771479›Full record

ReviewFrontiers in medicine2025

Applications and advances of multi-omics technologies in gastrointestinal tumors.

Yuqing Liu, Feng Gao, Yang Cheng, Liang Qi, Haining Yu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Decoding the Role of Lipid Metabolism and Membrane Dynamics in Melanoma.International journal of molecular sciences · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. From gut to mouth: salivary signatures of carcinogenic microbiota.Frontiers in cellular and infection microbiology · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuqing Liu *Medical Equipment Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Feng Gao *Medical Equipment Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Yang ChengMedical Equipment Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Liang QiMedical Equipment Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Haining YuMedical Equipment Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal tumors pose a significant clinical challenge due to their high heterogeneity and the difficulties in early diagnosis. The article systematically reviews the latest advances in multi-omics technologies in gastrointestinal tumor research, focusing on their contributions to early screening, biomarker discovery, and treatment optimization. Genomics reveals genetic characteristics and heterogeneity of tumors; transcriptomics helps identify molecular subtypes and potential therapeutic targets; proteomics provides important information on core proteins and the immune microenvironment; and metabolomics offers promising biomarkers for early diagnosis. Furthermore, emerging fields such as epigenomics, metagenomics, and lipidomics, through the construction of multi-scale frameworks, have opened new paths for molecular subtyping and targeted therapy. By integrating these multi-dimensional data, multi-omics integration enables a panoramic dissection of driver mutations, dynamic signaling pathways, and metabolic-immune interactions. However, challenges such as data heterogeneity, insufficient algorithm generalization, and high costs limit clinical translation. In the future, the integration of single-cell multi-omics, artificial intelligence, and deep learning technologies with multi-omics may offer more efficient strategies for the precise diagnosis and personalized treatment of gastrointestinal tumors.

Indexed as

biomarkersearly screeninggastrointestinal tumorsmulti-omics technologiessingle-cell genomicstreatment optimization

Identifiers

PMID40771479
PMCPMC12325369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.